Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Costello

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 15, 2026
Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulationPhilip M Langer, Alison J Clare, Xudong Peng, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Lancet (London, England)|September 15, 2004
Effect of a participatory intervention with women's groups on birth outcomes in Nepal: cluster-randomised controlled trialDharma S Manandhar, David Osrin, Bhim Prasad Shrestha, et al.
Nucleic Acids Research|January 16, 1999
Identification of differentially expressed mRNAs in human fetal liver across gestationK Malhotra, K R Luehrsen, L L Costello, et al.
Nature Medicine|October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
British Journal of Haematology|February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial resultsPaul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Nature Communications|November 24, 2025
T<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trialHubert Tseng, Bhagirathbhai Dholaria, Stacey A Cranert, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 15, 2026
Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulationPhilip M Langer, Alison J Clare, Xudong Peng, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Lancet (London, England)|September 15, 2004
Effect of a participatory intervention with women's groups on birth outcomes in Nepal: cluster-randomised controlled trialDharma S Manandhar, David Osrin, Bhim Prasad Shrestha, et al.
Nucleic Acids Research|January 16, 1999
Identification of differentially expressed mRNAs in human fetal liver across gestationK Malhotra, K R Luehrsen, L L Costello, et al.
Nature Medicine|October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
British Journal of Haematology|February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial resultsPaul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Nature Communications|November 24, 2025
T<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trialHubert Tseng, Bhagirathbhai Dholaria, Stacey A Cranert, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.
Pageof 15